Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
08/2013
08/13/2013CA2570976C Methods of treatment of endobronchial infections
08/13/2013CA2570041C Process for the preparation of nateglinide
08/13/2013CA2569888C Use of l-carnitine for the treatment of cardiovascular diseases
08/13/2013CA2530113C Bioerodible sustained release drug delivery systems
08/13/2013CA2529647C Influenza hemagglutinin and neuraminidase variants
08/13/2013CA2504021C Compositions and methods for transdermal oxybutynin therapy
08/13/2013CA2488803C Use of ramoplanin to treat diseases associated with the use of antibiotics
08/13/2013CA2488102C Infant formula compositions containing lutein and zeaxanthin
08/13/2013CA2477236C Amino-substituted sulfonanilides and derivatives thereof for treating proliferative disorders
08/13/2013CA2464121C Pregnancy-associated plasma protein-a2 (papp-a2)
08/13/2013CA2455832C Method for dip coating medical devices with an aqueous latex polymeric emulsion
08/13/2013CA2393141C Novel methods for the treatment and prevention of ileus
08/13/2013CA2330741C Methods of forming protein-linked lipidic microparticles, and compositions thereof
08/13/2013CA2258277C Characterization of granulocytic ehrlichia and methods of use
08/13/2013CA2225377C Novel tgf-.beta. like cytokine
08/09/2013WO2012103575A1 Compositions and methods for the treatment of nasal passages
08/09/2013CA2852591A1 Compositions and methods for the treatment of nasal passages
08/08/2013WO2013116823A1 Benzimidazoles and uses thereof
08/08/2013WO2013116821A1 Compositions comprising ndga derivatives and sorafenib and their use in treatment of cancer
08/08/2013WO2013116786A1 Cdk8/cdk19 selective inhibitors and their use in anti-metastatic and chemopreventative methods for cancer
08/08/2013WO2013116781A1 Alk1 antagonists and their uses in treating renal cell carcinoma
08/08/2013WO2013116765A1 Ribonucleotide reductase inhibitors and methods of use
08/08/2013WO2013116753A1 Fatty acids as anti-inflammatory agents
08/08/2013WO2013116730A1 Combination therapy comprising tenofovir alafenamide hemifumarate and cobicistat for use in the treatment of viral infections
08/08/2013WO2013116721A1 Retinaldehyde mimetics and inhibitors of retinaldehyde dehydrogenase i in the treatment of disorders
08/08/2013WO2013116720A1 Combination therapy comprising tenofovir alafenamide hemifumarate and cobicistat for use in the treatment of viral infections
08/08/2013WO2013116715A1 Methods and intermediates for preparing pharmaceutical agents
08/08/2013WO2013116713A1 Treating neuropathic pain with seh inhibitors
08/08/2013WO2013116691A1 Methods for improving muscle strength
08/08/2013WO2013116682A1 Macrocyclic compounds for modulating il-17
08/08/2013WO2013116663A1 Novel cysteine protease inhibitors and uses thereof
08/08/2013WO2013116657A1 USE OF LAQUINIMOD FOR TREATING CROHN'S DISEASE PATIENTS WHO FAILED FIRST-LINE ANTI-TNFα THERAPY
08/08/2013WO2013116605A1 Compositions for the treatment of tuberculosis and methods of using same
08/08/2013WO2013116592A1 Once daily treatment of hepatitis c with ribavirin and taribavirin
08/08/2013WO2013116590A1 Inhibition of pattern recognition receptors in pancreatic cancer treatment using tlr inhibitors
08/08/2013WO2013116589A1 Methods for diagnosing and treating learning or mental disorders
08/08/2013WO2013116562A1 Compositions and methods of treating a disease with (s)-4 amino-6-((1-(5-chloro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile
08/08/2013WO2013116538A1 Methods of preventing and treating diabetes by inhibiting serotonin synthesis
08/08/2013WO2013116491A1 Carboxamide, sulfonamide and amine compounds and methods for using them
08/08/2013WO2013116413A1 Diazabicyclo[3.3.1]nonanes, methods of synthesis, and uses thereof
08/08/2013WO2013116383A1 Non-anticoagulant sulfated or sulfonated synthetic polymers
08/08/2013WO2013116382A1 Purinone compounds as kinase inhibitors
08/08/2013WO2013116366A1 Non-anticoagulant sulfated or sulfonated polysaccharides
08/08/2013WO2013116339A1 High potency formulations of vx-950
08/08/2013WO2013116325A1 Improving postural stability administering droxidopa
08/08/2013WO2013116293A1 Combination of a rtk inhibitor with an anti - estrogen and use thereof for the treatment of cancer
08/08/2013WO2013116291A1 Imidazo [4, 5 - b] pyridine derivatives as alk and jak modulators for the treatment of proliferative disorders
08/08/2013WO2013116281A1 Combination therapy including isophosphoramide mustard, analogs, or salts thereof
08/08/2013WO2013116228A1 Compounds and methods for inhibition of ap endonuclease-1/ redox factor-1 (hape1) activity
08/08/2013WO2013116194A2 Method of treating or limiting development of heart failure with preserved ejection fraction and tissue fibrosis
08/08/2013WO2013116186A1 Brimonidine for treating visual disorders mediated by central visual projections from the eye
08/08/2013WO2013116182A1 Heterocyclic compounds as inhibitors of leukotriene production
08/08/2013WO2013116174A1 Mglu 2/3 agonists
08/08/2013WO2013116150A1 Spinal fusion system for osteoporotic vertebrae
08/08/2013WO2013116075A1 Benzyl sulfonamide derivatives useful as mogat - 2 inhibitors
08/08/2013WO2013116065A1 Novel morpholinyl derivatives useful as mogat-2 inhibitors
08/08/2013WO2013116062A1 Salt replacement compositions and methods of using same
08/08/2013WO2013115966A1 Cyclodextrin-based polymers for therapeutic delivery
08/08/2013WO2013115916A1 Combination therapy comprising gs-7340 and cobicistat for use in the treatment of viral infections
08/08/2013WO2013115884A2 Pyridopyrimidinone inhibitors of viruses
08/08/2013WO2013115859A2 Heat shielded composite panel
08/08/2013WO2013115793A1 Iron chelators and uses thereof
08/08/2013WO2013115746A1 A production method for (effervescent) pharmaceutical compositions comprising an alpha - glucosidase inhibitor (miglitol) and metformin
08/08/2013WO2013115745A1 A process for production of pharmaceutical (effervescent) composition comprising alpha - glucosidase inhibitor (e.g. vogliobose and metformin)
08/08/2013WO2013115744A1 A process for production of pharmaceutical (effervescent) composition comprising alpha - glucosidase inhibitor (e.g. vogliobose and metformin)
08/08/2013WO2013115743A1 Effervescent tablet formulations comprising the combination of voglibose and metformin
08/08/2013WO2013115742A1 Pharmaceutical composition comprising alpha-glucosidase inhibitor
08/08/2013WO2013115741A1 Pharmaceutical compositions comprising alpha-glucosidase inhibitor
08/08/2013WO2013115740A1 Synergisctic combination comprising a meglitinide derivative and lipoic acid
08/08/2013WO2013115739A1 Production method for formulations comprising comprising nateglinide and lipoic acid
08/08/2013WO2013115738A1 Micronized acarbose
08/08/2013WO2013115636A1 Composition for the treatment and/or prevention of fatty liver disease
08/08/2013WO2013115535A1 Novel crystalline acid addition salt of tricyclo derivative compound or hydride thereof, and production method therefor
08/08/2013WO2013115486A1 Novel piperine derivative and use therefor
08/08/2013WO2013114416A1 Lyophilized tablets of escitalopram oxalate for sublingual administration
08/08/2013WO2013114413A1 Diethyl- [6- (4-hydroxycarbamoyl-phenyl-carbamoyloxy-methyl) - naphthalen-2-yl-methyl] -ammonium chloride for use in the treatment of muscular dystrophy
08/08/2013WO2013114410A1 A composition and use thereof in the treatment of anal rhagades
08/08/2013WO2013114403A1 Substituted 4,5-dihydro-2h-benzo[e]indazole-9-carboxylates for the treatment of diabetes and related disorders
08/08/2013WO2013114390A1 Gastro retentive drug delivery system of calcium supplements
08/08/2013WO2013114389A1 Process for preparing solid oral formulations comprising low dose of entecavir
08/08/2013WO2013114382A1 Crystalline darunavir
08/08/2013WO2013114339A1 Combination therapy for cancer using hsp27 inhibitor and egfr tyrosine kinase inhibitors or anti-folates
08/08/2013WO2013114332A1 4-(benzoimidazol-2-yl)-thiazole compounds and related aza derivatives
08/08/2013WO2013114296A1 Iron chelators and uses thereof
08/08/2013WO2013114283A1 Gastroretentive tablets
08/08/2013WO2013114281A1 Pregabalin gr tablets
08/08/2013WO2013114232A1 Process for preparation of crystalline form l of ilaprazole
08/08/2013WO2013114231A1 Treated apertures
08/08/2013WO2013114204A1 A method of using adenosine and dipyridamole for pharmacologic stress testing, with specific compositions, unit dosage forms and kits
08/08/2013WO2013114113A1 1h-pyrrolo[2,3-b] pyridine derivatives and their use as kinase inhibitors
08/08/2013WO2013113860A1 Fused pyrroledicarboxamides and their use as pharmaceuticals
08/08/2013WO2013113857A1 (1r,4r)-6'-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4',9'-dihydro-3'h-spiro-[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine for treating fibromyalgia and chronic fatigue syndrome
08/08/2013WO2013113841A1 Novel therapeutic agents
08/08/2013WO2013113838A1 Novel therapeutic agents
08/08/2013WO2013113799A1 Phenyl -c-oxadiazole derivatives as inhibitors of leukotriene production combination therapy
08/08/2013WO2013113765A1 Hydroxyalkyl starch for the treatment of head and neck cancers by reduction of tumor growth rates
08/08/2013WO2013113747A1 Hydroxyalkyl starch for the treatment of cancers by reduction of tumor growth rates
08/08/2013WO2013113722A1 Anti-invasive compounds
08/08/2013WO2013113690A1 Pharmaceutical patch for transdermal administration of (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4-b]indol]-4-amine
08/08/2013WO2013113669A1 Isoquinoline and naphthyridine derivatives
1 ... 606 607 608 609 610 611 612 613 614 615 616 617 618 619 620 621 622 623 624 625 626 ... 7860